Overview of the multifaceted resistances toward EGFR-TKIs and new chemotherapeutic strategies in non-small cell lung cancer
The role of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) has been vastly studied over the last decade. This has led to the rapid development of many generations of EGFR tyrosine kinase inhibitors (EGFR-TKIs). However, patients treated with third-generation TKIs (osim...
Saved in:
Main Authors: | Dzulkeflee, Rashidi, Leong, Kok Hoong, Ogawa, Satoshi, Bignon, Jerome, Chan, Mun Chiang, Kong, Kin Weng |
---|---|
Format: | Article |
Published: |
Elsevier
2022
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/40814/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
by: Chai, Chee Shee, et al.
Published: (2019) -
Real-world multicentre experience of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer
by: Liam, Chong Kin, et al.
Published: (2019) -
Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance
by: Zhang, Chuanfen, et al.
Published: (2022) -
Surface peptide functionalization of zeolitic imidazolate framework-8 for autonomous homing and enhanced delivery of chemotherapeutic agent to lung tumor cells
by: Mohd Abdul Kamal, Nurul Akmarina, et al.
Published: (2021) -
Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma
by: Poh, Mau Ern, et al.
Published: (2018)